Pharmacokinetics
The mean plasma concentration-time curves are illustrated inFigure 2 (fasting) and Figure 3 (fed). A biphasic
decline manner was shown, which initially decrease rapidly and described
a somewhat decrease. Besides, the concentration-time curve of gefitinib
was similar as for R and T formulations. Pharmacokinetic parameters of
gefitinib under fasting and fed conditions were presented inTable 2 . AUC0-t accounted for ≥90% of the
total AUC0-∞ for all subjects, indicating that the
plasma concentration-time profiles were represented nicely. The CV
values of the pharmacokinetic parameters were similar with more than
50%. It is noted that the mean Cmax and AUC were in the
range of 208.01-260.05 ng/mL, 6520.42-7334.52 h*ng/mL. In addition, the
meant t1/2 was in the range of 29.50-35.10 hour.
Moreover, no significant differences were detected in either the
absorption or elimination phases of the R- and T-formulations of
gefitinib, with similar values of pharmacokinetic parameters under
fasting and feeding conditions. Figure 2 and Figure 3 also
demonstrated the generally consistent absorption as described using
concentration-time curve of post-administration of 12 hour.